Arcutis Biotherapeutics, Inc.
ARQT
$26.23
$0.311.20%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 232.88% | -164.93% | 134.75% | 146.64% | 36.61% |
| Total Depreciation and Amortization | 0.18% | -0.18% | 0.18% | -0.18% | -81.10% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 18.89% | 5.97% | 3.28% | -2.86% | 12.05% |
| Change in Net Operating Assets | -1,007.15% | 176.91% | 88.34% | -488.92% | 128.99% |
| Cash from Operations | 464.49% | -91.45% | 1,592.87% | -641.36% | 101.07% |
| Capital Expenditure | -- | -- | -- | 100.00% | 87.17% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -32.95% | 66.85% | -35.38% | -244.26% | 41.62% |
| Cash from Investing | -34.35% | 66.85% | -35.38% | -244.91% | 48.28% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 180.22% | -71.33% | 152.17% | 6.96% | 249.37% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 86.50% | -71.33% | 152.17% | 6.96% | 249.37% |
| Foreign Exchange rate Adjustments | 61.34% | -301.69% | 162.11% | -147.50% | 4,900.00% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 92.13% | -93.33% | 83.56% | -232.56% | 206.01% |